The Impact of Antifungal Prophylaxis in Lung Transplant Recipients.

Kelly M Pennington, Hayley J Dykhoff, Xiaoxi Yao, Lindsey R Sangaralingham, Nilay D Shah, Steve G Peters, Jason N Barreto, Raymund R Razonable, Cassie C Kennedy

Annals of the American Thoracic Society 2021 Mar

filter terms:

Rationale: Many lung transplant centers prescribe antifungal medications after transplantation to prevent invasive fungal infections (IFIs); however, the effectiveness of antifungal prophylaxis at reducing the risk of all-cause mortality or IFI has not been established.Objectives: We aimed to evaluate the effect of antifungal prophylaxis on all-cause mortality and IFI in lung transplant patients.Methods: Using administrative claims data, we identified adult patients who underwent lung transplantation between January 1, 2005, and December 31, 2018. Propensity score analysis using inverse probability treatment-weighting approach was used to balance the differences in baseline characteristics between those receiving antifungal prophylaxis and those not receiving antifungal prophylaxis. Cox proportional hazards regression was used to compare rates of all-cause mortality and IFI in both groups.Results: We identified 662 lung transplant recipients (LTRs) (387 received prophylaxis and 275 did not). All-cause mortality was significantly lower in those receiving antifungal prophylaxis compared with those not receiving antifungal prophylaxis (event rate per 100 person-years, 8.36 vs. 19.49; hazard ratio, 0.43; 95% confidence interval, 0.26-0.71; P = 0.003). Patients receiving antifungal prophylaxis had a lower rate of IFI compared with those not receiving prophylaxis (event rate per 100 person-years, 14.94 vs. 22.37; hazard ratio, 0.68; 95% confidence interval, 0.44-1.05; P = 0.079), but did not reach statistical significance.Conclusions: In this real-world analysis, antifungal prophylaxis in LTRs was associated with reduced all-cause mortality compared with those not receiving antifungal prophylaxis. Rates of IFI were also lower in those receiving prophylaxis, but this was not statistically significant in our primary analysis.

Citation

Kelly M Pennington, Hayley J Dykhoff, Xiaoxi Yao, Lindsey R Sangaralingham, Nilay D Shah, Steve G Peters, Jason N Barreto, Raymund R Razonable, Cassie C Kennedy. The Impact of Antifungal Prophylaxis in Lung Transplant Recipients. Annals of the American Thoracic Society. 2021 Mar;18(3):468-476